Risultati della ricerca - Jan Müller‐Brand

  • Mostra 1 - 14 risultati su 14
Raffina i risultati
  1. 1
    Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium

    Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium di A Blumberg, H.W. Roser, C Zehnder, Jan Müller‐Brand

    Pubblicazione 1997
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  2. 2
    The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease

    The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease di Martin A. Walter, R Melzer, Christian Schindler, Jan Müller‐Brand, Alan Tyndall, Egbert Nitzsche

    Pubblicazione 2005
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  3. 3
    The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study

    The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study di Martin A. Walter, Christian P. Turtschi, Christian Schindler, Peter Minnig, Jan Müller‐Brand, Beat P. Müller‐Stich

    Pubblicazione 2007
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  4. 4
    In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study

    In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study di Flavio Forrer, Jianhua Chen, Melpomeni Fani, P. Powell, Andreas Lohri, Jan Müller‐Brand, Gerhard Moldenhauer, Helmut R. Maëcke

    Pubblicazione 2009
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  5. 5
    Somatostatin Receptor–Targeted Radiopeptide Therapy with <sup>90</sup>Y-DOTATOC and <sup>177</sup>Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial

    Somatostatin Receptor–Targeted Radiopeptide Therapy with <sup>90</sup>Y-DOTATOC and <sup>177</sup>Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Tri... di Nicolas Marincek, Piotr Radojewski, Rebecca A. Dumont, Philippe Brunner, Jan Müller‐Brand, Helmut R. Maëcke, Matthias Briel, Martin A. Walter

    Pubblicazione 2015
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  6. 6
    Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial

    Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial di Dominik Cordier, Flavio Forrer, Frank Bruchertseifer, Alfred Morgenstern, Christos Apostolidis, Stephan Good, Jan Müller‐Brand, Helmut R. Mäcke, J.C. Reubi, Adrian Merlo

    Pubblicazione 2010
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  7. 7
    Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials

    Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials di Martin A. Walter, Matthias Briel, Mirjam Christ‐Crain, Steen Joop Bonnema, John Connell, David S. Cooper, Heiner C. Bucher, Jan Müller‐Brand, Beat P. Müller‐Stich

    Pubblicazione 2007
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  8. 8
    Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours

    Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours di Anna Romer, Daniela Seiler, Nicolas Marincek, Philippe Brunner, Michael Koller, Quinn K.T. Ng, Helmut R. Maëcke, Jan Müller‐Brand, Christoph Rochlitz, Matthias Briel, Christian Schindler, Martin A. Walter

    Pubblicazione 2013
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    Cohort Study of Somatostatin-Based Radiopeptide Therapy With [<sup>90</sup>Y-DOTA]-TOC Versus [<sup>90</sup>Y-DOTA]-TOC Plus [<sup>177</sup>Lu-DOTA]-TOC in Neuroendocrine Cancers

    Cohort Study of Somatostatin-Based Radiopeptide Therapy With [<sup>90</sup>Y-DOTA]-TOC Versus [<sup>90</sup>Y-DOTA]-TOC Plus [<sup>177</sup>Lu-DOTA]-TOC in Neuroendocrine Cancers di Linda Villard, Anna Romer, Nicolas Marincek, Philippe Brunner, Michael Koller, Christian Schindler, Quinn K.T. Ng, Helmut R. Mäcke, Jan Müller‐Brand, Christoph Rochlitz, Matthias Briel, Martin A. Walter

    Pubblicazione 2012
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  10. 10
    Progression to Overt or Silent CAD in Asymptomatic Patients With Diabetes Mellitus at High Coronary Risk

    Progression to Overt or Silent CAD in Asymptomatic Patients With Diabetes Mellitus at High Coronary Risk di Michael J. Zellweger, Michael Maraun, Hans H. Osterhues, Ulrich Keller, Jan Müller‐Brand, Raban Jeger, Otmar Pfister, Thilo Burkard, Friedrich Eckstein, Stefanie von Felten, Stefan Osswald, Matthias Pfisterer

    Pubblicazione 2014
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  11. 11
    Procalcitonin levels predict clinical course and progression‐free survival in patients with medullary thyroid cancer

    Procalcitonin levels predict clinical course and progression‐free survival in patients with medullary thyroid cancer di Martin A. Walter, Christian Meier, Tanja Radimerski, Fabienne Iten, Marius Kränzlin, Jan Müller‐Brand, Jan Willem B. de Groot, Ido P. Kema, Thera P. Links, Beat P. Müller‐Stich

    Pubblicazione 2009
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  12. 12
    Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors

    Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors di Nancy Sharma, Boris G. Naraev, Eric G. Engelman, M. Bridget Zimmerman, David Bushnell, Thomas M. O’Dorisio, M. Sue O’Dorisio, Yusuf Menda, Jan Müller‐Brand, James R. Howe, Þorvarður R. Hálfdánarson

    Pubblicazione 2016
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  13. 13
    The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors

    The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors di Philippe Brunner, Ann-Catherine Jörg, Katharina Glatz, Lukas Bubendorf, Piotr Radojewski, M Umlauft, Nicolas Marincek, Petar-Marko Spanjol, Thomas Krause, Rebecca A. Dumont, Helmut R. Maëcke, Jan Müller‐Brand, Matthias Briel, Anja Schmitt, Aurel Perren, Martin A. Walter

    Pubblicazione 2016
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  14. 14
    The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis

    The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis di Martin Fuchs, Matthias Briel, Thomas Daikeler, Ulrich A. Walker, Helmut Rasch, Scott Berg, Quinn K.T. Ng, Heike Raatz, David Jayne, Ina Kötter, Daniël Blockmans, María C. Cid, Sergio Prieto‐González, Peter Lamprecht, Carlo Salvarani, Zaharenia Th. Karageorgaki, Richard A. Watts, Raashid Luqmani, Jan Müller‐Brand, Alan Tyndall, Martin A. Walter

    Pubblicazione 2011
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: